The Center for Applied Research Sciences (CARS) supports the effective, efficient and safe conduct of clinical trials at Washington University School of Medicine, one of the nation’s leading academic medical research institutions. The CARS helps to recruit patients into appropriate clinical trials and provides sponsoring institutions with the full spectrum of clinical trial support services.

For Patients
The CARS offers study volunteers the opportunity to advance medical science by participating in clinical trials. Volunteers may visit the CARS’s Volunteer for Health Registry at vfh.wustl.edu to learn about the participation experience, browse current studies and register as a potential study volunteer.

For Sponsors
The CARS is a one-stop, full-service resource for companies committed to the highest quality clinical studies. The CARS provides sponsors with access to nationally renowned investigators and top-quality study coordinators and clinical trial participants, as well as a full spectrum of support services.

Services include:

• Study Placement
• Regulatory and Budget Services
• Targeted Patient Recruitment
• Expert Study Coordination
• Center for Advanced Medicine Services
• Ancillary Services

Please visit ccs.wustl.edu for more information.

Washington University School of Medicine is among the world's largest academic biomedical research centers. From its central location in St. Louis, Missouri, the School's world-renowned clinical investigators, nationally ranked hospital partners, cutting-edge research facilities and large, diverse patient population form the ideal environment for sponsoring clinical research.

World-Renowned Clinical Investigators

• 1,635 faculty — more than 200 in clinical research
• 100 faculty named in America's Top Doctors, 2005
• Nation's third-largest academic clinical practice: 976 physicians in more than 50 specialties

Ideal Enrollment Environment

• 731,706 on-campus patient visits, FY 2006
• Patients drawn from 13 area hospitals
• Catchment area of nine Midwestern states and beyond
• High patient compliance and retention rates
• Comprehensive services for industry partners including study placement, strategic recruitment, and IRB submission through the University's Center for Applied Research Sciences

Where Bench and Bedside Meet

• Top 5 nationally in National Institutes of Health funding ($359 million in FY 2006)
• 1,500 ongoing clinical trials
• Affiliated with Barnes-Jewish Hospital* and St. Louis Children's Hospital,** — both ranked among the nation's 10 best, with 1,478 beds combined — and the Alvin J. Siteman Cancer Center, a National Cancer Institute Comprehensive Cancer Center

Exceptional Data Integrity
As one of the world's leading academic research institutions, Washington University School of Medicine upholds an uncompromising commitment to quality in all of its efforts, including research.

Medical Firsts:
A Sampling of Major Discoveries from Washington University School of Medicine

• Published the first evidence linking smoking with lung cancer.
• Performed the first successful lung removal.
• Developed the key tool in today's standard blood test for detecting heart damage in heart attacks: the monoclonal antibody Conan-MB.
• Established the PSA blood test as the most accurate method for early diagnosis of prostate cancer.
• Served as one of three major contributors on the international team that produced the finished human genome sequence.
• With international collaborators, sequenced the first genome of a multicellular organism: C. elegans.
• First to complete the gene sequence of an entire chromosome, for chromosome Y.
• First to use yeast artificial chromosomes to study hereditary diseases in humans.
• Created the first positron emission tomography (PET) scanner.
• Discovered aspirin's role in preventing heart attacks.
• Pioneered research into excitotoxicity and brain injury.
• Grew embryonic animal tissue transplants into fully functional kidneys in an animal host.
• Helped pioneer the use of insulin to treat diabetes.
• Performed the first magnetic stereotactic brain surgery to biopsy a human brain tumor.
• Discovered the key players in programmed cell death.
• Pioneered the use of endoscopic techniques for abdominal and cardiothoracic surgery.
• Performed the first laparoscopic kidney removal.
• Performed the world's first nerve transplant using nerve tissue from a cadaver donor.
• Generated cells that reinsulate nerve axons and improve mobility in rats.
• Developed a genetic test that detects whether an individual will develop a form of thyroid cancer, leading to the first surgical prevention of cancer based on genetic test results.
• Developed a rating scale used worldwide to diagnose Alzheimer's disease.
• Developed a new strategy for creating vaccines and antibiotics against bacteria such as those that infect the bladder.
• Developed a surgery to remove damaged portions of emphysema patients' lungs — the first effective surgical treatment for the disease.
• Developed a cure for hepatitis B in cases diagnosed early.
• Created the Maze procedure, a surgical cure for atrial fibrillation.
• Performed the nation's first larynx restoration surgery.
• Helped pioneer cochlear implant technology.
• Demonstrated that bacteria, not stress, cause ulcers.
• Pioneered the use of surgery and medication to lower eye pressure in glaucoma patients to prevent further vision loss.

Ongoing research includes:

• Studying the effects of alcohol and anesthesia on the developing brain.
• Improving pain management strategies for children.
• Developing and using nanoparticles for molecular imaging and targeted drug delivery for cancer and clogged arteries.
• Imaging language areas in adult and pediatric brains during recovery from stroke to observe natural rehabilitation patterns.
• Developing drug therapies for histoplasmosis and malaria.
• Determining how microorganisms naturally residing in the gut contribute to human health and disease.
• Investigating weight loss approaches including low-carbohydrate diets, liposuction, gastric bypass surgery and extreme caloric restriction.
• Developing and using new imaging tools to study how nervous system cells form connections.
• Determining the mechanism by which antidepressant medications work in the brain.
• Exploring potential links between the tendency to be thin or overweight and the composition of microbes living in the gut.
• Identifying anatomical and genetic markers of schizophrenia.
• Leading efforts to identify the underlying cause of recurrent urinary tract infections.
• Developing treatments to compensate for individual genetic traits that interfere with drug performance.

Please visit research.medicine.wustl.edu for more information.

The Center for Applied Research Sciences (CARS) supports the effective, efficient and reliable evaluation of new pharmaceuticals and medical devices in collaboration with sponsoring organizations. The CARS is a one-stop, full-service resource providing a full spectrum of support services, in collaboration with the School of Medicine’s Inpatient and Outpatient Research Units and the Core Laboratory for Clinical Studies

Center for Applied Research Sciences

Study Placement

• Expediting study placement
• Identifying outstanding clinical investigators and researchers with unique skills, training or equipment

Regulatory and Budget Services

• Facilitating all IRB and regulatory services
• Comprehensive study budget preparation and negotiation
• Consultation as needed between the PI and clinical study sponsor

Targeted Patient Recruitment

• Performing subject recruitment, pre-screening and enrollment
• Access to a centralized database of potential patient volunteers to facilitate rapid accrual of and access to study participants
• Assistance with creating a comprehensive approach to maximizing recruitment efforts
• Advertising development and placement

Expert Study Coordination

• Providing the full range of study coordinator services from site initiation to study close-out
• Eight clinical research coordinators, seven of which are RNs, two ACRP-certified and one data control coordinator available from pre-site visit to closeout visit

Outpatient Research Unit

• 5,700 square feet of dedicated outpatient research space allocated
• Five fully equipped exam rooms and two long-term areas for extended study visits
• Phlebotomy and lab processing
• Space for monitoring visits via Internet
• Fully stocked crash cart

Ancillary Services

• Core Laboratory for Clinical Studies (special handling and central lab services)
• Adult or Pediatric General Clinical Research Center (facilities and nursing care)
• Hospital inpatient facilities and services
• Biostatistics consultation or services
• Core radiology studies
• Outcome evaluation
• Decision and cost-benefits analyses

Please visit ccs.wustl.edu for more information.

Inpatient Research Unit

The Washington University Inpatient Research Unit (IRU) is an on-campus comprehensive support center for inpatient and outpatient adult and pediatric research. The IRU provides inpatient and outpatient research space, research nursing, dietary and data management assistance, biostatistical consultation and core laboratory services. The IRU is among the largest and most comprehensive in the country and has been supported continuously by the National Institutes of Health since 1960.

Its most recent competitive renewal application includes nearly 100 research protocols, several with multiple projects, from principal investigators based in eight departments. The bulk of the protocols are classical patient-oriented research including molecular biology, immunology, physiology, pathophysiology, as well as new approaches to prevention, diagnosis and treatment. Disorders under study include heart disease, hypertension, diabetes, dyslipidemia, osteoporosis and other age-related problems, obesity, depression, schizophrenia, infectious diseases including AIDS, asthma, sickle cell disease, neurological disorders including Alzheimer's disease, autoimmune diseases and endocrinopathies including multiple endocrine neoplasia.

Methods used include measures of gene expression and genotype; cerebral and myocardial metabolism with positron emission tomography; cognitive functions; glucose/lipid/protein kinetics and cholesterol absorption with stable and radioactive isotopes, in some instances paired with tissue microdialysis; and organ structure with magnetic resonance imaging.

Please visit gcrc.wustl.edu for more information.

Core Laboratory for Clinical Studies

The Core Laboratory for Clinical Studies (CLCS) at Washington University School of Medicine is a CLIA-certified clinical laboratory specializing in the support of clinical research studies of all sizes and complexities. Founded in 1972, the CLCS has more than 30 years experience in providing clinical trial support to government, industry and university sponsors. The lab has successfully participated in cardiovascular, women's studies and diabetes trials.

The CLCS provides the following:

• Regulated Environment: Meet the requirements and regulations in 21 Code of Federal Regulations (CFR), and 29 CFR, Part 1910.1450.
• Established Responsibilities and Services Rendered: A 'Statement of Work' or 'Protocol specification' is created to establish lab responsibilities and timeline commitments.
• Supplies Maintenance to Sites: A controlled process to supply extraction kits is used to avoid use of expired tubes.
• Long-Term Freezing: A database to keep track of all stored specimens is used. This database facilitates quick retrieval of samples.
• Experience in Electronic Data Exchange: Electronic data can be provided in various formats since our laboratory information system has been developed in-house.
• Standardized HbA1c and Lipids Testing: The CLCS participates in the National Glycohemoglobin Standardization Program and the Lipid Standardization Program.

In addition to providing pharmaceutical clinical trial support, the CLCS works closely with manufacturers of diagnostics devices and provides services to facilitate assay/instrument development. Capabilities range from recruiting defined study participants to analytical evaluation of new or newly formulated reagents and analyzers. The CLCS is also a resource for diagnostic assay development and new method evaluation.

Please visit clcs.wustl.edu for more information.

Since its inception in 1891, Washington University School of Medicine has been a pioneer and leader in biomedical research, contributing countless major advances in nearly every area of medical inquiry. The School’s faculty is internationally recognized for their leadership in landmark national and international clinical studies. Today, more than 1,500 clinical trials, conducted in strict compliance with FDA regulations, are in progress. In 2006, 1,100 new studies were initiated.

The Washington University School of Medicine faculty is comprised of world leaders in research in arthritis, bone and mineral diseases, cancer, cardiovascular disease, child health, diabetes, gastrointestinal diseases, genetics, genome sequencing, imaging, immunology, infectious diseases, molecular design, neuroscience, ophthalmology, pediatrics, pulmonary disease, renal disease, thrombosis and surgery.

Nineteen Nobel laureates have been associated with the School of Medicine, 12 faculty members belong to the National Academy of Sciences and 24 are members of the academy's Institute of Medicine. In addition, 93 faculty members hold individual career development awards from the National Institutes of Health (NIH), 19 have MERIT status -- a special recognition given by the NIH that provides long-term, uninterrupted financial support -- and six are Howard Hughes Medical Institute investigators.

Study patients are drawn largely from the clinical activities of Washington University Medical Center. Washington University operates the nation's third largest academic clinical practice group, called Washington University Physicians, made up of 976 physicians in more than 50 specialties and subspecialties. Washington University Physicians provide comprehensive care at more than 35 clinical office sites throughout the St. Louis area.

Washington University Physicians Clinical Activities, FY 2006:

• Physician Outpatient Visits: 675,345
• Hospital Admissions: 56,361 (BJH, SLCH)
• Outpatient Procedures: 684,059

Through its affiliations with Barnes-Jewish Hospital and St. Louis Children's Hospital, Washington University also has access to the patient pool of BJC HealthCare. BJC is a consortium of 13 area hospitals -- including Barnes-Jewish and St. Louis Children's hospitals -- and is one of the nation's largest non-profit health care providers. In total, BJC experiences roughly 727,000 patient contacts annually (combined hospital admissions, home health visits and emergency department visits).

Diversity

Washington University draws patients from a nine-state Midwestern area and beyond. Its patient pool covers urban, suburban and rural areas and represents a full range of ages and ethnic and socioeconomic parameters. Within the city of St. Louis, 52 percent of the population is African-American; in the region as a whole, 24 percent of the population is considered diverse. St. Louis gains diversity as a major national center for refugee placement; with nearly 85,000 refugees, St. Louis city is second in the nation for the density of new arrivals to native born. To serve patients and their families, Barnes-Jewish Hospital’s Refugee Health and Interpreter Services offers a team of nearly 30 interpreters who provide services through at least 32,000 encounters each year in more than 60 languages.

Compliance and Retention

Washington University's study participants consistently rate well above national averages in compliance rates and retention.

Hospitals and Affiliates

Washington University School of Medicine is affiliated with several elite patient care institutions: Barnes-Jewish Hospital, St. Louis Children's Hospital and the Alvin J. Siteman Cancer Center. Together with the Central Institute for the Deaf, these institutions make up Washington University Medical Center.

Barnes-Jewish Hospital

Barnes-Jewish Hospital, a 1,228-bed facility, is the largest hospital in Missouri. The hospital is ranked ninth nationally among an elite group of the nation's best academic hospitals by U.S. News & World Report. Barnes-Jewish ranks in the top 10 in ear/nose/throat (5), endocrinology (7), heart and heart surgery (10), kidney disease (8), neurology and neurosurgery (7), ophthalmology (10) and respiratory disorders (6). It ranks among the top 20 in cancer (19), digestive disorders (18), geriatrics (14), orthopedics (14), , psychiatry (15), rheumatology (17) and urology (12). The medical staff is composed exclusively of Washington University School of Medicine faculty physicians.

Cancer Care:
The Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital is the only National Cancer Institute-designated Comprehensive Cancer Center within a 240-mile radius of St. Louis. Siteman offers a multidisciplinary team of more than 300 preeminent clinicians and medical researchers.

Heart Care:
The Washington University Heart Care Institute at Barnes-Jewish Hospital has pioneered many procedures, from the Cox-Maze procedure through ablation therapies to valve repair and replacement and permanent implantation of ventricular assist devices. Its patients were among the first to benefit from advanced angioplasty techniques, coronary bypass procedures, valvuloplasty and heart transplantation including total artificial heart. Divisions of heart services include: heart failure and transplant, cardiac surgery and minimally-invasive cardiac surgery, cardiac rehabilitation and heart disease prevention, cardiac intensive care, interventional cardiology, electrophysiology, echocardiography, centers for diseases of the aorta, valvular heart disease, congenital heart disease, and marfan syndrome.

Lung Care:
Advanced areas include lung cancer surgery, esophageal cancer surgery, lung volume reduction surgery (invented at Washington University) to treat COPD, transcervical thymectomy to treat myasthenia gravis, lung transplantation and lung nodule monitoring.

Transplant Services:
Barnes-Jewish Hospital has the only comprehensive transplant center in the region, offering heart, heart and lung, lung, double lung, kidney, liver, pancreas islet cell and bone marrow transplants. In addition to achieving outcomes that meet or beat national averages, the transplant program is known for quality and continuity of care.

Orthopedics:
From adult reconstruction and joint replacement to sports medicine and trauma, Barnes-Jewish provides the highest level of orthopedic care. The sports medicine specialists care for two of St. Louis’ professional teams: The St. Louis Rams and the St. Louis Blues.

Neurological Care:
Highlights include a Neurosurgery/Neuroradiology Center for managing cerebral aneurysms and arteriovenous malformations; Gamma Knife Center for minimally invasive treatment of brain tumors; comprehensive care for epilepsy, multiple sclerosis, neuromuscular disease, dementia and stroke; stereotactic neurosurgery; and deep brain stimulation for movement disorders.

Radiologic Care:
The Mallinckrodt Institute of Radiology at Barnes-Jewish Hospital provides full diagnostic procedures including computed tomography, nuclear medicine and interventional radiology. The Institute has pioneered many radiological milestones including becoming the first in Missouri to combine PET and CT scanning.

Trauma Care:
Barnes-Jewish Hospital has the only American College of Surgeons-verified level-one trauma center in Missouri, Illinois and Arkansas. Barnes-Jewish Hospital was named one of the top five highly prepared trauma centers in the United States by the National Foundation for Trauma Care in September 2006.

Barnes-Jewish Hospital by the Numbers, 2006
Physicians: 1,707
Licensed Beds: 1,228
Inpatient Admissions: 53,907
Inpatient Surgeries: 16,822
Outpatient Surgery Visits: 17,847
Outpatient Registrations: 468,132
Emergency Department Visits: 77,847

Please visit barnesjewish.org for more information.

St. Louis Children's Hospital

St. Louis Children's Hospital, staffed exclusively by Washington University School of Medicine faculty physicians, is ranked among the best children's hospitals in the country, and provides a full range of pediatric specialty and subspecialty services to a primary service region covering six states. The hospital has 250 licensed beds, including a 26-bed pediatric intensive care unit, a 75-bed Level III newborn intensive care unit and a five-bed pediatric bone marrow transplant unit. Child magazine ranks St. Louis Children's Hospital seventh in the country — second in pulmonary medicine, sixth in neonatology and eighth in orthopedic care. U.S. News & World Report ranks Children's Hospital 14th nationally.

By the Numbers
Patients served annually: 275,000
Licensed beds: 250
Employees: 2,700
Medical staff members: 700

Children's Hospital is one of the top pediatric transplant centers in the country. It is the world's leading pediatric lung transplant program, having performed more than 310 lung and heart-lung transplants. The hospital also has transplant programs for heart, liver, kidney, small intestine and bone marrow. The hospital was the site of the world's first pediatric split-liver transplant and in 2004 performed the first of three successful ABO-incompatible heart transplants, in which donor and recipient have unmatched blood types; approximately 50 such transplants have been performed in the world. It is one of a select few pediatric facilities nationwide certified to perform bone marrow transplants from unrelated donors.

St. Louis Children's Hospital provides superlative heart care services, including a full array of diagnostic techniques, many of which are non-invasive and were developed or perfected there. In 2004, physicians at Children's Hospital implanted a pacemaker in the world's youngest recipient, a 4-month-old girl. The hospital also offers a world-class cardiac catheterization lab that provides surgical alternatives to repair heart defects, and it runs one of the country's largest pediatric heart failure programs.

The hospital excels in many other areas of care as well. It has one of the largest pediatric neurology departments in the country, with the nation's second-largest pediatric cerebral palsy program, and is among the most comprehensive specialized epilepsy centers in the world. The hospital offers a Level I Pediatric Trauma Center and is one of a handful of centers across the country to develop an advanced surgical suite exclusively for minimally invasive surgical procedures. It runs the nation's second-largest cystic fibrosis center and is one of the country's top three for immunologic and rheumatological disorders. In addition, St. Louis Children's Hospital is a national leader in treatment and research regarding asthma, diabetes and sickle cell disease, and it operates one of the country's largest cochlear implant programs. Please visit stlouischildrens.org for more information.

BJC HealthCare

Barnes-Jewish Hospital and St. Louis Children's Hospital are members of BJC HealthCare, one of the largest nonprofit health care organizations in the United States. BJC is a regional, nonprofit health care organization that provides community-based and academic health care services through 13 hospitals and more than 100 inpatient and ambulatory care sites in Missouri and southern Illinois. BJC provides a full continuum of services including wellness and health promotion; primary, acute and ambulatory care; skilled nursing; long-term care; home health care and hospice care.

BJC HealthCare Highlights
Employees: 26,622
Physicians: 3,790
Staffed beds: 3,508
Hospital admissions: 145,584
Home health visits: 195,501
Emergency department visits: 386,247

BJC's major affiliated hospitals are Barnes-Jewish Hospital, St. Louis Children's Hospital, Christian Hospital and Missouri Baptist Medical Center in St. Louis, and Boone Hospital Center in Columbia, Missouri. BJC's affiliated community hospitals include Alton Memorial Hospital, Barnes-Jewish St. Peters Hospital, Barnes-Jewish West County Hospital, Clay County Hospital, Parkland Health Center and Missouri Baptist Hospital-Sullivan. BJC HealthCare and HealthSouth are partners in The Rehabilitation Institute of St. Louis. BJC's newest hospital, Progress West HealthCare Center, serves St. Charles County.

Please visit bjc.org for more information.

The Alvin J. Siteman Cancer Center

The Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital is an international leader in cancer treatment, research, prevention, education and community outreach. It is the only cancer center within a 240-mile radius of St. Louis to hold the prestigious Comprehensive Cancer Center designation from the National Cancer Institute and membership in the National Comprehensive Cancer Network.

Siteman offers the expertise of more than 350 Washington University researchers and physicians who provide care for more than 7,000 newly diagnosed cancer patients each year. A full range of advanced diagnostic and treatment services are available for patients with all types of cancer, from common diseases to rare bone, soft-tissue and adrenal gland cancers.

The Alvin J. Siteman Cancer Center brings together more than 260 scientists who move new cancer therapies from bench to bedside. This process is enhanced by patient access to more than 350 clinical studies, including collaborations with other leading cancer centers. Scientists and physicians affiliated with Siteman hold $130 million in cancer research and related training grants. Their work spans the full spectrum from basic science, to translational and clinical investigation, to oncologic imaging, to prevention and control. Research is organized into eight programs, described below.

Research Programs

Cancer and Developmental Biology (CDB)
CDB Program investigators use model organisms to study oncogenes, oncogenic processes and developmental pathways, and to test potential cancer therapies.

Cancer Genetics
This signature Siteman program works to identify and characterize genetic defects in distinct human malignancies, which is the basis for the development of more accurate and sensitive methods for cancer diagnosis and therapy. This program builds on the expertise of the renowned Washington University Genome Sequencing Center and Siteman’s contributions to the Cancer Biomedical Informatics Grid (caBIG).

Cellular Proliferation
This program is organized around the idea that elucidating the connections among signal transduction pathways, cell cycle regulatory pathways and checkpoint pathways will help define origins of human cancer and identify targets for development of novel therapies and diagnostic tools. Research focuses on fundamental biological processes regulating cellular proliferation, including signal transduction, cell cycle regulation and checkpoint control.

Hematopoietic Development and Malignancy (HDM)
The HDM Program studies the biology of hematopoietic stem cells in health and disease. Genetic mutations in stem cells or early hematopoietic progenitors are thought to be the cause of most types of hematopoietic malignancy. Program members currently are identifying these mutations in patients with many forms of cancer.

Oncologic Imaging
The Oncologic Imaging Program research includes developing new imaging agents to assess tumor therapy, investigating agents designed to monitor multidrug resistant modulators, developing new techniques in molecular imaging, and applying imaging techniques for evaluation and planning of radiation treatment. This program utilizes the new Center for Clinical Imaging Research, a unique resource nationally.

Prevention and Control
This program works to prevent cancer, reduce its morbidity and mortality, and improve quality of life for patients by focusing efforts in nicotine dependence, smoking cessation, early detection, epidemiology, cancer communication and intervention.

Translational and Clinical Research
The members of this program work to translate cutting-edge laboratory-based science into novel cancer diagnostic agents and treatments. This group of investigators works within disease workgroups (such as breast or GI) and on particular types of centers. This program has been recognized by the NCI with a nanotechnology center, the Siteman Center of Cancer Nanotechnology Excellence (SCCNE), which is dedicated to speeding new highly targeted molecules into clinical practice.

Tumor Immunology
The Tumor Immunology Program focuses on immune system development, antigen processing and presentation, lymphocyte biology, cytokine biology and biochemistry and tumor immunotherapy. The long-range goal is to facilitate direct translation of cutting-edge tumor immunology research into novel immunotherapeutic protocols.

Please visit siteman.wustl.edu for more information.

Washington University and Industry Partnerships

As one of the leading medical research institutions in the United States, Washington University is positioned to collaborate effectively with industry partners in clinical research. The goal for partnerships with industry is the translation of basic research discoveries into products and services for the improvement of human health and well-being.

Washington University takes pride in having formed major corporate collaborations that respect the needs of companies and maintain the principles and autonomy of the academic process and culture. The University’s faculty is knowledgeable and responsive to the needs of our corporate partners, and they understand and meet the expectations of contractual agreements. Together, the University and its partners accomplish what neither is capable of alone.

The university strives to structure agreements that protect the integrity of both the corporation and the university, allowing each to pursue its strengths with assistance from the other. Each agreement is negotiated on a case-by-case basis to take into account the diversity of our constituencies. Marketable Results

Corporate sponsorship of Washington University research puts industry on the front line for early identification of product development opportunities. Timely access to diversified, high-quality biotechnology discoveries gives industry a competitive edge in bringing promising products to market — extending the reach of your in-house R&D and allowing your company to move swiftly into and out of new areas of inquiry.

The University's primary goal in all contract negotiations is to build lasting relationships with corporate sponsors. The University proactively licenses faculty inventions to companies, seeking win-win partnerships that allow the commercial potential of these inventions to be realized.

Faculty often participates in the further development of licensed technology through a sponsored research agreement. These agreements often involve sharing of materials and facilities, moving the invention quickly toward practical applications. Through strategic licensing of University technology, corporate sponsors can obtain the use of new materials to develop products in a timely manner.

Products now on the market based on Washington University technology include a leading diagnostic test for myocardial infarction based on a monoclonal antibody to creatine kinase MB, an improved diagnostic test for herpes simplex virus, a molecular genetic system to study programmed cell death in cancer, a safer type of breast implant, a revolutionary method for treating diabetes based on transplantation of pancreatic islet cells, and a breast cancer antigen for immunotherapy of adenocarcinoma.

Master Agreements

For quicker and more efficient contract negotiation, Washington University establishes master agreements with select industry partners. Once a master agreement is established with a given partner, it covers all current and future collaborations with that partner, avoiding the need to negotiate separate contracts for each project.

CenterWatch is listing the following trials that are actively recruiting patients at this center.

• Are you down in the dumps with your diabetes?
• Pre-diabetes: Are you at risk?
• This is a nonrandomized, blinded study of the role of hemodynamic factors in the risk of subsequent stroke in medically and surgically treated patients with Moyamoya disease

For more information, please contact:

Stephanie White
Co-Director, Recruitment Enhancement Core
Washington University in St. Louis - Center for Applied Research Sciences
660 S. Euclid, Campus Box 8009
St. Louis, MO 63110 USA
Phone: 314-362-0819
Fax: 314-747-1404
E-mail:

If you are interested in contacting this center to discuss placing a clinical trial there, please complete and send the E-mail form below. A representative from the research center will then follow up with you.

Name:
Address:
City:
State:
Zip:
Phone:
Email address:
Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

Last updated on March 10, 2008

PAC>